Ye Le, Mei Qiyong, Li Mingli, Gu Minghong, Ai Zisheng, Tang Kun, Shi Dongping, Wu Xiaotong, Wang Xiangrui, Zheng Yongjun
Department of Pain Management, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200127.
Pain Med. 2015 Apr;16(4):782-90. doi: 10.1111/pme.12664. Epub 2015 Feb 26.
The treatment of plantar heel pain is highly challenging. We report ultrasound-guided pulsed radiofrequency treatment (UG-PRF) in the gastrocnemius to treat plantar heel pain and minimize the safety issues.
This study compared UG-PRF with sham treatment in 100 patients with plantar heel pain. Primary outcome measures include the pain subscale of the Foot Health Status Questionnaire (FHSQ-pain) and "first step" pain as measured on a visual analogue scale (VAS-"first-step" pain). The secondary outcome measures include the FHSQ-foot function and general foot health, and health related quality of life (assessed using the Short Form-36 questionnaire [SF-36]). All outcomes were measured at 3 and 6 months post-treatment.
The results showed the efficacy of UG-PRF in terms of pain management, as reflected by higher FHSQ-pain score (increased by 20.0 (P < 0.0001) and 17.9 (P = 0.001) compared with the sham treatment at 3 or 6 months, respectively) and lower VAS-"first-step" pain (reduced by 26.1 (P < 0.0001) and 14.3 (P = 0.01) compared with the sham group at 3 or 6 months, respectively). The FHSQ-foot function and FHSQ-general foot health were increased by the UG-PRF (P < 0.05, vs sham treatment at 3 or 6 months). The SF-36 physical component score in the sham group was 10.8 (P = 0.042) and 10.4 (P = 0.044) lower than the UG-PRF group at 3 or 6 months, respectively. No severe complications were observed.
We conclude that the UG-PRF is both safe and efficacious in managing plantar heel pain.
足跟足底疼痛的治疗极具挑战性。我们报告了在腓肠肌进行超声引导下脉冲射频治疗(UG-PRF)以治疗足跟足底疼痛并将安全问题降至最低。
本研究将100例足跟足底疼痛患者的UG-PRF与假治疗进行比较。主要结局指标包括足部健康状况问卷疼痛分量表(FHSQ-疼痛)以及视觉模拟量表测量的“第一步”疼痛(VAS-“第一步”疼痛)。次要结局指标包括FHSQ足部功能和足部总体健康状况,以及健康相关生活质量(使用简明健康状况调查问卷[SF-36]进行评估)。所有结局指标均在治疗后3个月和6个月进行测量。
结果显示UG-PRF在疼痛管理方面具有疗效,这体现在FHSQ-疼痛评分更高(与假治疗相比,3个月和6个月时分别增加20.0(P < 0.0001)和17.9(P = 0.001))以及VAS-“第一步”疼痛更低(与假治疗组相比,3个月和6个月时分别降低26.1(P < 0.0001)和14.3(P = 0.01))。UG-PRF使FHSQ足部功能和FHSQ足部总体健康状况得到改善(与3个月或6个月时的假治疗相比,P < 0.05)。假治疗组的SF-36身体成分评分在3个月和6个月时分别比UG-PRF组低10.8(P = 0.042)和10.4(P = 0.044)。未观察到严重并发症。
我们得出结论,UG-PRF在治疗足跟足底疼痛方面既安全又有效。